
Tango Therapeutics, Inc.: updates and filings
Price
$22.06
November 20, 2026Market cap $3.7B
What Ploutos Investor adds for Tango Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 9, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Results of operationsForm8-K
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 23, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Other material eventsForm8-K
- Aug 11, 2026Results of operationsForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 7, 2026Officer or director change, Regulation FD disclosure (amendment)Form8-K/A
- Aug 6, 2026Officer or director changeForm8-K
- Jun 23, 2026Officer or director changeForm8-K
- Jun 10, 2026Material agreement enteredForm8-K
- Jun 8, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 4, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 23, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | 8-K | Other material events | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 7, 2026 | 8-K/A | Officer or director change, Regulation FD disclosure (amendment) | Document |
| Aug 6, 2026 | 8-K | Officer or director change | Document |
| Jun 23, 2026 | 8-K | Officer or director change | Document |
| Jun 10, 2026 | 8-K | Material agreement entered | Document |
| Jun 8, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 4, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 30, 2020.
The full analysis
What do Tango Therapeutics's filings show?
The filings are where every one of Tango Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.